SCHEMBL288626

SCHEMBL288626

O=C(O)c1ccc2nccc-2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.44
USP2 O75604 1/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
KDM4C Q9H3R0 5/20 0.42
P4HA1 P13674 2/20 0.42
PIN1 Q13526 2/20 0.40
KDM5C P41229 6/20 0.40
KDM2A Q9Y2K7 5/20 0.40
KDM3A Q9Y4C1 5/20 0.40
KDM4A O75164 5/20 0.40
KDM6B O15054 4/20 0.40
HCAR2 Q8TDS4 1/20 0.39
KDM5B Q9UGL1 3/20 0.37
TET3 O43151 1/20 0.37
BBOX1 O75936 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
KDM5A P29375 1/20 0.37
ASPH Q12797 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2295486 0.83 MKNK1 (0.39) KDM4EKDM4CP4HA1KDM5CKDM2A
Hydrochloric Acid SCHEMBL19211726 0.81 MKNK1 (0.38) KDM4EKDM4CP4HA1KDM5CKDM2A
SCHEMBL30415076 0.79 PTPN11 (0.46) KDM4EMAPTCYP4F2CYP4A11
SCHEMBL23416991 0.78 KDM4E (0.58) KDM4EUSP2HPGDHSD17B10P4HA1
SCHEMBL23416948 0.78 KDM4E (0.42) KDM4EUSP2HPGDHSD17B10P4HA1
SCHEMBL23416974 0.78 KDM4E (0.42) KDM4EUSP2HPGDHSD17B10P4HA1
SCHEMBL1219786 0.77 EGLN1 (0.44) KDM4EKDM4CKDM2AKDM3AKDM6B
SCHEMBL23416932 0.74 KMT2A (0.43) KDM4EUSP2HPGDHSD17B10ALDH1A1
SCHEMBL9750144 0.74 KDM4E (0.63) KDM4EUSP2HPGDHSD17B10PIN1
SCHEMBL29933891 0.74 HCAR2 (0.48) KDM4EUSP2HPGDHSD17B10KDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10849881-B2 Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl HOFFMANN-LA ROCHE INC. (US) 2020-12-01 US disclosed
US-20200339570-A1 BICYCLIC DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2020-10-29 US disclosed
CN-109952302-A Muscarine M1 receptor forward direction allosteric modulators 苏文生命科学有限公司 2019-06-28 CN disclosed
US-20180280352-A1 OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL HOFFMANN-LA ROCHE INC. (US) 2018-10-04 US disclosed
US-20170050960-A1 NEW BICYCLIC DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2017-02-23 US disclosed
WO-2016160677-A1 COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2016-10-06 WO disclosed
EP-2427450-A1 GPR 119 MODULATORS Pfizer Inc. (US) 2012-03-14 EP disclosed
EP-2427448-A1 Gpr 119 modulators Pfizer Inc. (US) 2012-03-14 EP disclosed
WO-2010128414-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 WO disclosed
WO-2010128425-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180280352-A1 OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL NPY1R, NPY2R, DECR1 KDM4E 1536/4885USP2 2438/4885HPGD 3958/4885
US-20170050960-A1 NEW BICYCLIC DERIVATIVES BICRA, CCNY, UQCRB KDM4E 1849/4885USP2 4558/4885HPGD 1949/4885
US-20200339570-A1 BICYCLIC DERIVATIVES CCNY, BICRA, UQCRB KDM4E 1613/4885USP2 4634/4885HPGD 2461/4885
US-10849881-B2 Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl NPY1R, NPY2R, DECR1 KDM4E 1515/4885USP2 2441/4885HPGD 4077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.